HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fluorocarbon Polymers

Also Known As:
Fluoropolymer; Polymer, Fluorinated; Polymer, Fluorocarbon; Polymers, Fluorinated; Polymers, Fluorocarbon; Resin, Fluorocarbon; Resins, Fluorocarbon; Fluorinated Polymer; Fluorinated Polymers; Fluorocarbon Polymer; Fluorocarbon Resin; Fluorocarbon Resins; Fluoropolymers
Networked: 75 relevant articles (5 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Stone, Gregg W: 6 articles (01/2022 - 04/2008)
2. Iida, Osamu: 3 articles (01/2022 - 06/2021)
3. Brown, W Morris: 3 articles (01/2022 - 12/2016)
4. Sabik, Joseph F: 3 articles (01/2022 - 12/2016)
5. Serruys, Patrick W: 3 articles (01/2022 - 12/2016)
6. Virmani, Renu: 3 articles (01/2022 - 09/2017)
7. Mano, Toshiaki: 2 articles (01/2022 - 01/2022)
8. Takahara, Mitsuyoshi: 2 articles (01/2022 - 01/2022)
9. Cheng, Qi: 2 articles (01/2022 - 03/2019)
10. Crowley, Aaron: 2 articles (01/2022 - 11/2019)

Related Diseases

1. Neoplasms (Cancer)
2. Coronary Artery Disease (Coronary Atherosclerosis)
04/23/2008 - "A thin, cobalt-chromium stent eluting the antiproliferative agent everolimus from a nonadhesive, durable fluoropolymer has shown promise in preliminary studies in improving clinical and angiographic outcomes in patients with coronary artery disease. "
12/20/2019 - "First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial."
11/07/2019 - "We randomly assigned 1905 patients with left main coronary artery disease of low or intermediate anatomical complexity (according to assessment at the participating centers) to undergo either PCI with fluoropolymer-based cobalt-chromium everolimus-eluting stents (PCI group, 948 patients) or CABG (CABG group, 957 patients). "
12/08/2016 - "We randomly assigned 1905 eligible patients with left main coronary artery disease of low or intermediate anatomical complexity to undergo either percutaneous coronary intervention (PCI) with fluoropolymer-based cobalt-chromium everolimus-eluting stents (PCI group, 948 patients) or CABG (CABG group, 957 patients). "
01/01/2022 - "We sought to examine long-term outcomes of patients with left main coronary disease (LMCAD) randomized to PCI with fluoropolymer-based cobalt-chromium everolimus-eluting stents or CABG according to treatment at discharge with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in the large-scale, multicenter, randomized EXCEL trial. "
3. Thrombosis (Thrombus)
4. Fibrosis (Cirrhosis)
5. Hypoxia (Hypoxemia)

Related Drugs and Biologics

1. Polymers
2. Everolimus
3. Cobalt
4. Chromium
5. Albumins
6. Oxygen (Dioxygen)
7. Reactive Oxygen Species (Oxygen Radicals)
8. Polytetrafluoroethylene (Teflon)
9. Sirolimus (Rapamycin)
10. Angiotensin Receptor Antagonists

Related Therapies and Procedures

1. Stents
2. Drug-Eluting Stents
3. Therapeutics
4. Immunotherapy
5. Renal Dialysis (Hemodialysis)